{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-005236","form_type":"8-K","ticker":"TVGN","cik":"0001860871","company_name":"Tevogen Bio Holdings Inc.","filed_at":"2025-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.225229+00:00","generated_at":"2026-05-23T12:19:48.879386+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Tevogen Bio inks related-party facility deal with CD8 for cell therapy production","bullets":["Agreement with CD8 Technology Services (associated with >5% holder Dr. Manmohan Patel) for turn-key GMP cell therapy production facility.","Tevogen to provide primary staff and operations; facility supports both pre-clinical research and GMP production.","Initial term of 12 months, auto-renewing; specific costs, scope, and timelines to be set in future work orders.","Agreement formalizes previously announced letter of intent and aligns with previously stated topline forecasts."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-005236","json":"https://secwatch.observer/filing/0001641172-25-005236.json","markdown":"https://secwatch.observer/filing/0001641172-25-005236.md","text":"https://secwatch.observer/filing/0001641172-25-005236.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860871/000164117225005236/0001641172-25-005236-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860871/000164117225005236/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T12:19:48.879386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}